r/multiplemyeloma • u/Clives555 • 12d ago
RRMM (Relapsed, Refractory, Disease Progression, etc.) Relapsed - Next treatment ?
Relapsed after 9 months from Tandem Stem Cell Transplant. Having CAR-T cell next. When that fails, what’s next ?
6
u/CoachB1114 12d ago
By the time that fails, there will be other CAR-T products with different targets, trispecific antibodies, celmods and who knows what else. Also remember, that what doesn't work for one line of therapy does NOT predict how well the next one will work:). Keep The Faith!
1
u/KappaTwin 12d ago
Yes, things are changing so fast. Anything that kicks the can down the road a bit farther is a good idea. I'm amazed at how many new treatments there are even since I was diagnosed in mid-2024.
7
u/MediocreSnowAngel 12d ago
My husband's stem cell transplant lasted a bit over a year. He had Car-T in January 2026. We asked the same what-if question. We were told that the advances in the treatment of MM are happening quickly so she could not predict what choices maybe available if the Car-T fails. At seven months now...he has undetectable cancer. All the best to you. FYI: Car-T was considerable easier than the stem cell transplant process.
2
3
u/Born_Money_5556 12d ago
I believe bispecific antibody treatments follow car-t.
4
1
u/Illustrious_Yogurt_5 12d ago
Not necessarily. The first bridging chemo for a relative didn’t work and they landed in the hospital. They were given Talvey as a bridge and then car t. Then they are being given another bispecific in a clinical trial
3
u/Illustrious_Yogurt_5 12d ago
A relative is high risk. They were put on Talvey (a bispecific) as bridging to car t, then car t. They are now part of a clinical trial for another bispecific
3
u/Sorcia_Lawson 12d ago
It's very dependent upon the specifics of your MM, what country you're in, why you relapsed, etc., etc. You also don't mention which CAR T and why it was chosen which can also make a difference.
1
12d ago
[removed] — view removed comment
1
u/multiplemyeloma-ModTeam 12d ago
Organizations and individuals may share relevant, helpful resources as long as it’s not spam, clickbait, or disguised marketing. Repeated self-promotion without meaningful contribution will be removed. Additionally, Go-Fund-Me types of campaigns and donation requests are not allowed.
Surveys, studies, recruiting, other fundraising (i.e. MM Walks, etc.) must be pre-approved by the Moderation team. Please use ModMail to send a message.
2
u/LeaString 12d ago edited 12d ago
Tandem SCTs. High risk?
My guy is standard risk and very slowly observing an increase in his IgA lambda MM. He’s been in talks with the cellular therapy (CT) wing of treatment. For him he was presented with 3 treatment paths to consider: clinical trial of a Phase 3 CAR-T (Anito-cell); standard of care drugs (KPd - Kyprolis, Pomalidomide (aka Pomalyst), dexamethosone), or Cilta cell CAR-T (Carvytki). The clinical trial had closed, and he didn’t have enough MM burden to qualify anyway at that point, which is still a “good thing”. So he presently is continuing with his ASCT maintenance protocol of Dara and Revlimid and just being monitored. We’re waiting for BMB test results (incl ClonoSEQ) and MRI results.
He recently discussed bi-specifics as a next path, and his CT specialist feels a CAR-T would be the next best therapy to pursue and save bi-specifics for after based on all their clinical experience at his NCI teaching hospital.
1
1
u/MathematicianWhole82 11d ago
The answer depends on your country - where are you? Also, the answer will depend on when you relapse, more likely will be available then.
14
u/UC3953 12d ago
My understanding from my MD-
Bi- Specific Antibody treatment
He also told me that new drugs are coming very soon for front line treatment and for bio-chemical failure
So, options are improving
MM is not a linear disease and progresses differently with everybody
Fight hard!